e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Lung cancer: prognostic factors and features of oncogene-driven tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Exploring the 24h-effect of targeted therapies in non-small cell lung cancer from exon array blood profiling using dually constrained correspondence analysis
Florent Baty (St. Gallen, Switzerland), Florent Baty, Martin Brutsche
Source:
International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Session:
Lung cancer: prognostic factors and features of oncogene-driven tumours
Session type:
Thematic Poster Session
Number:
4239
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Florent Baty (St. Gallen, Switzerland), Florent Baty, Martin Brutsche. Exploring the 24h-effect of targeted therapies in non-small cell lung cancer from exon array blood profiling using dually constrained correspondence analysis. Eur Respir J 2015; 46: Suppl. 59, 4239
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib
Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer
Year: 2014
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Metabolic modification as a potential therapeutics approach in lung cancer
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Large-scale quantitative proteomic analysis identifies pathways in COPD-associated lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Exploiting metabolomic approaches to aid in the diagnosis of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Determining genomic rearrangements in clinical lung specimens for assessment of metastatic disease, actionable targets and disease monitoring
Source: International Congress 2016 – New genomic targets in pulmonary disease
Year: 2016
DNA methylation profiling of non-small cell lung cancer reveals an immune signature in COPD patients
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Telomere-associated gene network in lung adenocarcinoma
Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey
Year: 2015
Optimization of cfDNA routine use for NSCLC genomic alteration analysis
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP)
Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy
Year: 2013
Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept